OCT Clinical Unveils OCT Oncology™ Solution Package
OCT Clinical has announced the extension of its services via its OCT Oncology™ solution, to address needs in oncology clinical research, with a special focus on emerging biotechs.
To accomodate the specialized attention emerging oncology therapies often require, OCT Clinical focuses on accelerated access, speedy enrollment, and ultimately cost efficiency.
This is achievied with the help of digital solutions that emerging companies can benefit from:
- CTMS with real-time data access and data hub for risk management
- EDC roll-out tailored to early phase oncology (error-checking during data entry at sites allows for early detection and correction of errors to avoid additional costs associated with the double entry of data from paper-based forms)
- eCRF templates that also help to save time and resources
Read more about the new solution package here.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
